NeoGenomics (NASDAQ:NEO) Announces Earnings Results

NeoGenomics (NASDAQ:NEO) posted its quarterly earnings results on Tuesday. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), Zacks reports. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%.

NeoGenomics Price Performance

NeoGenomics stock opened at $12.40 on Wednesday. The firm’s 50-day moving average is $15.63 and its 200-day moving average is $15.57. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. NeoGenomics has a 1 year low of $10.69 and a 1 year high of $19.11.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research note on Friday, January 10th. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. The Goldman Sachs Group dropped their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Jefferies Financial Group started coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, Bank of America increased their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, NeoGenomics presently has an average rating of “Moderate Buy” and an average target price of $20.20.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.